

# Katia Pagnano

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1425170/katia-pagnano-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

123  
papers

974  
citations

16  
h-index

27  
g-index

130  
ext. papers

1,164  
ext. citations

2.8  
avg, IF

3.43  
L-index

#	Paper	IF	Citations
123	STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells. <i>Investigational New Drugs</i> , <b>2021</b> , 1	4.3	
122	Clinical Significance of Mitochondrial DNA Content in Acute Promyelocytic Leukemia. <i>Blood</i> , <b>2021</b> , 138, 3474-3474	2.2	
121	Final Results of the Fibromet Trial: An Open Label Phase II Study to Evaluate Metformin Effects on Bone Marrow Fibrosis and Disease Progression in Primary Myelofibrosis Patients. <i>Blood</i> , <b>2021</b> , 138, 2584-2584	2.2	0
120	COVID-19 in Patients with Chronic Myeloid Leukemia: Poor Outcomes for Patients with Comorbidities, Older Age, Advanced Phase Disease, and Those from Low-Income Countries: An Update of the Candid Study. <i>Blood</i> , <b>2021</b> , 138, 634-634	2.2	0
119	The Importance of Bone Marrow Lymphocyte Subtypes As Predicting Factors for Molecular Recurrence in Patients with Chronic Myeloid Leukemia after Discontinuation of Imatinib. <i>Blood</i> , <b>2021</b> , 138, 2564-2564	2.2	
118	A Survey Conducted during COVID-19 Pandemic Among Brazilian Chronic Myeloid Leukemia and Philadelphia-Negative Myeloproliferative Neoplasms Patients. <i>Blood</i> , <b>2021</b> , 138, 4601-4601	2.2	
117	Challenges in Chronic Myeloid Leukemia Management in South America. <i>Current Hematologic Malignancy Reports</i> , <b>2021</b> , 16, 440-447	4.4	
116	Second-line bosutinib (BOS) for patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML): Final 10-year results of a phase 1/2 study.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 7009-7009	2.2	2
115	Toll-like receptor gene polymorphisms in patients with myeloproliferative neoplasms. <i>Molecular Biology Reports</i> , <b>2021</b> , 48, 4995-5001	2.8	0
114	Metabolic shift of chronic myeloid leukemia patients under imatinib-pioglitazone regimen and discontinuation. <i>Medical Oncology</i> , <b>2021</b> , 38, 100	3.7	0
113	COVID-19 in chronic myeloid leukemia patients in Latin America. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 3212-3218	2.3	0
112	Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel. <i>Blood Advances</i> , <b>2021</b> , 5, 4855-4863	7.8	1
111	Philadelphia-positive B-lymphoblastic leukemia in a middle-income country - A real-world multicenter cohort. <i>Leukemia Research</i> , <b>2021</b> , 110, 106666	2.7	4
110	Guidelines for therapy of patients with chronic myeloproliferative neoplasms during the novel coronavirus SARS-CoV2 pandemic. <i>Hematology, Transfusion and Cell Therapy</i> , <b>2020</b> , 42, 195-199	1.6	
109	NTAL is associated with treatment outcome, cell proliferation and differentiation in acute promyelocytic leukemia. <i>Scientific Reports</i> , <b>2020</b> , 10, 10315	4.9	3
108	Developing a Simple Algorithm Based on Multiparameter Flow Cytometry for Fast Screening of Acute Promyelocytic Leukemia. <i>Blood</i> , <b>2020</b> , 136, 25-26	2.2	
107	COVID-19 in Chronic Myeloid Leukemia Patients - Brazilian Experience. <i>Blood</i> , <b>2020</b> , 136, 48-49	2.2	

106	COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLF) CML and COVID-19 (CANDID) Study. <i>Blood</i> , <b>2020</b> , 136, 46-47	2.2	10
105	Reduced SLIT2 is Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in Acute Promyelocytic Leukemia. <i>Cancers</i> , <b>2020</b> , 12,	6.6	3
104	Efficacy and safety of pioglitazone in a phase 1/2 imatinib discontinuation trial (EDI-PIO) in chronic myeloid leukemia with deep molecular response. <i>American Journal of Hematology</i> , <b>2020</b> , 95, E321-E323	7.1	4
103	Guideline on myeloproliferative neoplasms: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular: Project guidelines: Associação Médica Brasileira - 2019. <i>Hematology, Transfusion and Cell Therapy</i> , <b>2019</b> , 41 Suppl 1, 1-73	1.6	1
102	Management of chronic myeloid leukemia during pregnancy: a retrospective analysis at a single center. <i>Hematology, Transfusion and Cell Therapy</i> , <b>2019</b> , 41, 125-128	1.6	6
101	Combining gene mutation with gene expression analysis improves outcome prediction in acute promyelocytic leukemia. <i>Blood</i> , <b>2019</b> , 134, 951-959	2.2	16
100	Evaluation of anemia after long-term treatment with imatinib in chronic myeloid leukemia patients in chronic phase. <i>Hematology, Transfusion and Cell Therapy</i> , <b>2019</b> , 41, 329-334	1.6	4
99	Duration of Major Molecular Response and Discontinuation in Deep Molecular Response (MR4.5) Were Associated with Longer Treatment-Free Survival after Imatinib Discontinuation - Results from Two Prospective Brazilian Trials. <i>Blood</i> , <b>2019</b> , 134, 1655-1655	2.2	3
98	Pioglitazone Did Not Affect PPAR- $\gamma$ /STAT5, HIF2 $\alpha$ and CITED2 Gene Expression in Chronic Myeloid Leukemia Patients with Deep Molecular Response. <i>Blood</i> , <b>2019</b> , 134, 1637-1637	2.2	3
97	Analysis of Metformin Effects on Bone Marrow Fibrosis and Disease Progression in Primary Myelofibrosis Patients: Preliminary Results of an Open Label Phase II Trial (FIBROMET). <i>Blood</i> , <b>2019</b> , 134, 554-554	2.2	3
96	Financial Impact of Imatinib Discontinuation in Brazil - a Pharmoeconomic Study. <i>Blood</i> , <b>2019</b> , 134, 5844-5844	2.2	0
95	Clinical and Functional Studies Reveal That TP73 Isoforms Levels Are Associated with Prognosis and RA-Resistance in Acute Promyelocytic Leukemia. <i>Blood</i> , <b>2019</b> , 134, 2719-2719	2.2	0
94	Arsenic Trioxide Abrogate MN1 Mediated RA-Resistance in Acute Promyelocytic Leukemia. <i>Blood</i> , <b>2019</b> , 134, 5166-5166	2.2	0
93	Impact of Comorbidities on Survival of Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors. <i>Blood</i> , <b>2019</b> , 134, 2938-2938	2.2	0
92	Cardiovascular Risk and Cardiovascular Events in Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2019</b> , 19, 162-166	2	10
91	The experience of the International Consortium on Acute Promyelocytic Leukemia in monitoring minimal residual disease in acute promyelocytic leukaemia. <i>British Journal of Haematology</i> , <b>2018</b> , 180, 915-918	4.5	2
90	Treatment outcomes for Hodgkin lymphoma: First report from the Brazilian Prospective Registry. <i>Hematological Oncology</i> , <b>2018</b> , 36, 189-195	1.3	10
89	Lower socioeconomic status is independently associated with shorter survival in Hodgkin Lymphoma patients-An analysis from the Brazilian Hodgkin Lymphoma Registry. <i>International Journal of Cancer</i> , <b>2018</b> , 142, 883-890	7.5	6

88	Inflammatory picture of Philadelphia-negative myeloproliferative neoplasms. <i>Hematology, Transfusion and Cell Therapy</i> , <b>2018</b> , 40, 101-102	1.6	
87	Efficacy and Safety of Generic Imatinib Compared to Glivec in Chronic Phase - Chronic Myeloid Leukemia - a Multicenter, Observational Study. <i>Blood</i> , <b>2018</b> , 132, 46-46	2.2	3
86	B3a2 Transcript Is an Independent Factor for the Achievement of a Deep Molecular Response in Chronic Phase - Chronic Myeloid Leukemia Patients Treated with Imatinib in First-Line. <i>Blood</i> , <b>2018</b> , 132, 1749-1749	2.2	2
85	Improving the Outcomes of Acute Promyelocytic Leukemia in a Limited Resources Setting: The Benefit of Early ATRA Administration in 30-Day Survival. <i>Blood</i> , <b>2018</b> , 132, 5874-5874	2.2	1
84	Slit-Robo Pathway Is Clinically Relevant and May Represent a Potential Target in Acute Promyelocytic Leukemia. <i>Blood</i> , <b>2018</b> , 132, 1533-1533	2.2	
83	Metformin treatment Overcomes ATRA-Resistance in Acute Promyelocytic Leukemia and Increases FOXO3A Expression. <i>Blood</i> , <b>2018</b> , 132, 1532-1532	2.2	
82	Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2017</b> , 17, 728-733	2	16
81	BCR-ABL1-induced downregulation of WASP in chronic myeloid leukemia involves epigenetic modification and contributes to malignancy. <i>Cell Death and Disease</i> , <b>2017</b> , 8, e3114	9.8	6
80	BCR-ABL1 level monitoring in chronic myeloid leukemia by real time polymerase chain reaction in Brazil - not so real. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , <b>2017</b> , 39, 197-198		4
79	Clinical impact of expression in high-risk acute promyelocytic leukemia. <i>Blood Advances</i> , <b>2017</b> , 1, 1807-1814	7.8	8
78	The application of an integrated clinical, cytogenetic, and molecular risk stratification for acute myeloid leukemia patients using a central laboratory in a Brazilian multicentric study. <i>Blood Advances</i> , <b>2017</b> , 1, 86-89	7.8	78
77	Feasibility of minimal residual disease studies by multiparametric flow cytometry for acute myeloid leukemia in a developing country. <i>Blood Advances</i> , <b>2017</b> , 1, 80-83	7.8	78
76	Second-Line Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: An 8-Year Update. <i>Blood</i> , <b>2017</b> , 130, 900-900	2.2	1
75	Guidelines on the treatment of acute myeloid leukemia: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular: Project guidelines: Associação Médica Brasileira - 2015. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , <b>2016</b> , 38, 58-74		4
74	Age-adjusted international prognostic index is a predictor of survival in gastric diffuse B-cell non-Hodgkin lymphoma patients. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , <b>2016</b> , 38, 247-51		1
73	Clinical features of JAK2V617F- or CALR-mutated essential thrombocythemia and primary myelofibrosis. <i>Blood Cells, Molecules, and Diseases</i> , <b>2016</b> , 60, 74-7	2.1	4
72	Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients. <i>Blood Cells, Molecules, and Diseases</i> , <b>2016</b> , 57, 54-7	2.1	8
71	Influence of BCR-ABL Transcript Type on Outcome in Patients with Chronic-Phase Chronic Myeloid Leukemia Treated with Imatinib 400 Mg. <i>Blood</i> , <b>2016</b> , 128, 1911-1911	2.2	

70	Concomitant essential thrombocythemia with JAK2 V617F mutation in a patient with chronic myeloid leukemia with major molecular response with imatinib and long-term follow-up. <i>Oncology Letters</i> , <b>2016</b> , 12, 485-487	2.6	8
69	BCR-ABL1 Transcript Levels at 3 and 6 Months Are Better for Identifying Chronic Myeloid Leukemia Patients with Poor Outcome in Response to Second-Line Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure: A Report from a Single Institution. <i>Acta Haematologica</i> , <b>2015</b> , 134, 248-54	2.7	7
68	All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies. <i>Annals of Hematology</i> , <b>2015</b> , 94, 1347-56	3	24
67	BCR-ABL mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact on survival. <i>Cancer Investigation</i> , <b>2015</b> , 33, 451-8	2.1	13
66	Clinical outcomes of patients with acute myeloid leukemia: evaluation of genetic and molecular findings in a real-life setting. <i>Blood</i> , <b>2015</b> , 126, 1863-5	2.2	8
65	High Np73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia. <i>Blood</i> , <b>2015</b> , 126, 2302-6	2.2	22
64	JAK2 46/1 haplotype is associated with JAK2 V617F--positive myeloproliferative neoplasms in Brazilian patients. <i>International Journal of Laboratory Hematology</i> , <b>2015</b> , 37, 654-60	2.5	7
63	Assessment of Cardiovascular Events in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors. <i>Blood</i> , <b>2015</b> , 126, 4031-4031	2.2	1
62	Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors--a single center experience. <i>Clinics</i> , <b>2015</b> , 70, 550-53	2.3	11
61	Clinical Characteristics and Outcome of 104 Patients with Gastric Diffuse B-Cell Non-Hodgkin Lymphoma (DLBCL) a Multicenter Study. <i>Blood</i> , <b>2015</b> , 126, 5032-5032	2.2	
60	Identification of target genes using gene expression profile of granulocytes from patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. <i>Leukemia and Lymphoma</i> , <b>2014</b> , 55, 1861-9	1.9	6
59	Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study. <i>Annals of Hematology</i> , <b>2014</b> , 93, 2001-10	3	40
58	Protein-coding genes and long noncoding RNAs are differentially expressed in dasatinib-treated chronic myeloid leukemia patients with resistance to imatinib. <i>Hematology</i> , <b>2014</b> , 19, 31-41	2.2	12
57	Prognostic impact of KMT2E transcript levels on outcome of patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukaemia study. <i>British Journal of Haematology</i> , <b>2014</b> , 161, 510-6	4.5	10
56	Guidelines on the diagnosis and treatment for acute promyelocytic leukemia: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Guidelines Project: Associação Médica Brasileira - 2013. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , <b>2014</b> , 36, 71-92		13
55	Feasibility of Implementing Minimal Residual Disease Monitoring in Acute Promyelocytic Leukemia Patients Treated in Developing Countries. <i>Blood</i> , <b>2014</b> , 124, 5354-5354	2.2	
54	Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale. <i>Clinical Chemistry</i> , <b>2013</b> , 59, 938-48	5.5	38
53	Adherence to tyrosine kinase inhibitor therapy for chronic myeloid leukemia: a Brazilian single-center cohort. <i>Acta Haematologica</i> , <b>2013</b> , 130, 16-22	2.7	28

52	Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. <i>Blood</i> , <b>2013</b> , 121, 1935-43	2.2	77
51	Evaluation Of Seasonality In The Incidence Of Promyelocytic Leukemia In Brazil. <i>Blood</i> , <b>2013</b> , 122, 5005-5005		2
50	Primary Myelofibrosis Brazilian Patient Journey: From Initial Symptoms To Treatment. <i>Blood</i> , <b>2013</b> , 122, 5255-5255	2.2	1
49	Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome. <i>Clinics</i> , <b>2013</b> , 68, 339-43	2.3	7
48	Evaluation Of hOCT1 expression In Patients With Chronic Myeloid Leukemia (CML) Treated With Imatinib In First Line. <i>Blood</i> , <b>2013</b> , 122, 4041-4041	2.2	0
47	Treatment Results With Dasatinib Or Nilotinib In Third Line Therapy Of Chronic Myeloid Leukemia After Failure Of Two Tyrosine Kinase Inhibitors. <i>Blood</i> , <b>2013</b> , 122, 5189-5189	2.2	
46	Early Molecular Response Is Predictive Of Overall, Progression-Free and Event-Free Survival In Chronic Myeloid Leukemia Using Second-Generation Tyrosine Kinase Inhibitors After Imatinib Treatment. <i>Blood</i> , <b>2013</b> , 122, 1326-1326	2.2	
45	Evaluation Of Anemia After Long-Term Treatment With Imatinib In Chronic Myeloid Leukemia In Chronic Phase. <i>Blood</i> , <b>2013</b> , 122, 5200-5200	2.2	
44	Predictive Value Of Early Molecular Responses In Outcomes Of Patients With Chronic Myeloid Leukemia Treated With Imatinib In First-Line Therapy. <i>Blood</i> , <b>2013</b> , 122, 4941-4941	2.2	1
43	Prognostic Impact Of MLL5 transcript Levels On Outcome Of Patients With Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid and Anthracycline-Based Chemotherapy: An International Consortium On Acute Promyelocytic Leukemia Study. <i>Blood</i> , <b>2013</b> , 122, 2586-2586	2.2	
42	Molecular characteristics and chromatin texture features in acute promyelocytic leukemia. <i>Diagnostic Pathology</i> , <b>2012</b> , 7, 75	3	8
41	The impact of medical education and networking on the outcome of leukemia treatment in developing countries. The experience of International Consortium on Acute Promyelocytic Leukemia (IC-APL). <i>Hematology</i> , <b>2012</b> , 17 Suppl 1, S36-8	2.2	2
40	EUTOS Score Is Predictive of Event-Free Survival, but Not for Progression-Free and Overall Survival in Patients with Early Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib: A Single Institution Experience. <i>Blood</i> , <b>2012</b> , 120, 1681-1681	2.2	3
39	Philadelphia-negative chronic myeloproliferative neoplasms. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , <b>2012</b> , 34, 140-9		9
38	Chronic myeloid leukemia treatment guidelines: Brazilian Association of Hematology, Hemotherapy and Cell Therapy. Brazilian Medical Association Guidelines Project - 2012. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , <b>2012</b> , 34, 367-82		6
37	Aberrant Expression of the MLL5, BAALC, ID1, and WT1 Genes Is Associated with Higher Induction Mortality and Poorer Overall Survival in Acute Promyelocytic Leukemia Patients Treated with ATRA and Anthracycline-Based Chemotherapy: An International Consortium On Acute Promyelocytic Leukemia Study. <i>Blood</i> , <b>2012</b> , 120, 1407-1407	2.2	
36	Early Assessment of Molecular Response in Chronic Myeloid Leukemia Patients On Dasatinib After Imatinib Failure Identify Patients with Poor Cytogenetic and Molecular Responses. <i>Blood</i> , <b>2012</b> , 120, 3787-3787	2.2	
35	The Relationship Between the Regulation of TOB1 Gene with Cell Proliferation, Apoptosis and Cell Cycle in BCR-ABL Positive Cells. <i>Blood</i> , <b>2012</b> , 120, 5125-5125	2.2	

34	Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase - the importance of a major molecular response. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , <b>2011</b> , 33, 211-5		12
33	Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes. <i>Clinics</i> , <b>2011</b> , 66, 793-9	2.3	3
32	Brazilian experience using high dose sequential chemotherapy followed by autologous hematopoietic stem cell transplantation for malignant lymphomas. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , <b>2011</b> , 33, 432-8		1
31	Comparison Between RT-PCR and RQ-PCR for Minimal Residual Disease Detection in Acute Promyelocytic Leukemia: The International Consortium on Acute Promyelocytic Leukemia (IC-APL) Experience., <i>Blood</i> , <b>2011</b> , 118, 3552-3552	2.2	
30	Np73/TAp73 Expression Ratio Is Associated with Poor Outcome in Acute Promyelocytic Leukemia., <i>Blood</i> , <b>2011</b> , 118, 3536-3536	2.2	
29	Bcr-Abl Mutations in Chronic Myeloid Leukemia - Impact on Survival and Treatment with Second Generation Inhibitors A Study on Behalf of Latin American Leukemia Net (Lalnet). <i>Blood</i> , <b>2011</b> , 118, 1701-1701	2.2	
28	The Alteration of SEPT5 Gene Expression in BCR-ABL Positive Cells and Its Possible Correlation with the Development and / or Progression of Chronic Myeloid Leukemia (CML). <i>Blood</i> , <b>2011</b> , 118, 4415-4415	2.2	
27	Treatment outcome of acute promyelocytic leukemia with modified aida protocol. <i>Advances in Hematology</i> , <b>2010</b> , 2010, 672137	1.5	2
26	Current patient management of chronic myeloid leukemia in Latin America: a study by the Latin American Leukemia Net (LALNET). <i>Cancer</i> , <b>2010</b> , 116, 4991-5000	6.4	19
25	High Adherence to Tyrosine Kinase Inhibitors Seems to Be Related to Best Cytogenetic Responso In the Hasford Lower Risk Graup In Chronic Myeloid Leukemia.. <i>Blood</i> , <b>2010</b> , 116, 4477-4477	2.2	1
24	Chromatin Texture and Molecular Features Are Independent Prognostic Factors In AML. <i>Blood</i> , <b>2010</b> , 116, 4850-4850	2.2	1
23	Constitutive JunB expression, associated with the JAK2 V617F mutation, stimulates proliferation of the erythroid lineage. <i>Leukemia</i> , <b>2009</b> , 23, 144-52	10.7	12
22	Brazilian experience using high-dose sequential chemotherapy followed by autologous hematopoietic stem cell transplantation for relapsed or refractory Hodgkin lymphoma. <i>Clinical Lymphoma and Myeloma</i> , <b>2009</b> , 9, 449-54		2
21	New mutations detected by denaturing high performance liquid chromatography during screening of exon 6 bcr-abl mutations in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. <i>Leukemia and Lymphoma</i> , <b>2009</b> , 50, 1148-54	1.9	9
20	Improving the Treatment Outcome of Acute Promyelocytic Leukemia in Developing Countries through International Cooperative Network. Report On the International Consortium On Acute Promyelocytic Leukemia Study Group.. <i>Blood</i> , <b>2009</b> , 114, 6-6	2.2	7
19	The Gene RUNX1 and Its Possible Relation with the Alteration of Granulocytes Cells and with the Progression of Chronic Myeloid Leukemia.. <i>Blood</i> , <b>2009</b> , 114, 2215-2215	2.2	
18	Impact of Imatinib Dose Escalation in Chronic Myeloid Leukemia Patients in Chronic Phase with Sub-Optimal Response or Failure with Imatinib 400 Mg.. <i>Blood</i> , <b>2009</b> , 114, 3289-3289	2.2	
17	Gene Expression Profile in Responsive and Non-Responsive Chronic Myeloid Leukemia Patients Treated with Dasatinib.. <i>Blood</i> , <b>2009</b> , 114, 3260-3260	2.2	

16	Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. <i>Haematologica</i> , <b>2007</b> , 92, 1431-2	6.6	108
15	JAK2 V617F prevalence in Brazilian patients with polycythemia vera, idiopathic myelofibrosis and essential thrombocythemia. <i>Genetics and Molecular Biology</i> , <b>2007</b> , 30, 336-338	2	7
14	Screening of Mutations in BCR-ABL Kinase Domain in Chronic Myeloid Leukemia (CML) Patients Treated with Kinase Inhibitors by Denaturing High-Performance Liquid Chromatography (D-HPLC).. <i>Blood</i> , <b>2007</b> , 110, 4580-4580	2.2	
13	Brazilian Experience Using High Dose Sequential (HDS) Followed by Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Relapse/Refractory Aggressive Non-Hodgkin Lymphoma (NHL).. <i>Blood</i> , <b>2007</b> , 110, 5102-5102	2.2	
12	High Dose Sequential (HDS) Followed by Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Salvage Treatment of Hodgkin's Disease (HD): A Brazilian Experience.. <i>Blood</i> , <b>2007</b> , 110, 5103-5103	2.2	
11	Frontline therapy with early intensification and autologous stem cell transplantation versus conventional chemotherapy in unselected high-risk, aggressive non-Hodgkin's lymphoma patients: a prospective randomized GEMOH report. <i>Acta Haematologica</i> , <b>2006</b> , 115, 15-21	2.7	12
10	Detection of BCR-ABL Point Mutations in Patients with Chronic Myeloid Leukemia (CML) Resistant to Imatinib.. <i>Blood</i> , <b>2006</b> , 108, 4817-4817	2.2	
9	High-Dose Sequential Chemotherapy Versus a Less Intensive Chemotherapeutic Regimen Followed by Peripheral Blood Progenitor Cell Autografting in Patients with Advanced Hodgkin's Disease.. <i>Blood</i> , <b>2005</b> , 106, 5485-5485	2.2	
8	Os desafios no tratamento da Leucemia mielóide crônica na era do mesilato de imatinibe. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , <b>2004</b> , 26, 282		
7	Cutaneous adverse reaction to 2-chlorodeoxyadenosine with histological flame figures in patients with chronic lymphocytic leukaemia. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2004</b> , 18, 538-42	4.6	20
6	Apoptosis-regulating proteins and prognosis in diffuse large B cell non-Hodgkin's lymphomas. <i>Acta Haematologica</i> , <b>2002</b> , 107, 29-34	2.7	17
5	Mutations in the p53 gene in acute myeloid leukemia patients correlate with poor prognosis. <i>Hematology</i> , <b>2002</b> , 7, 13-9	2.2	20
4	p53, Mdm2, and c-Myc overexpression is associated with a poor prognosis in aggressive non-Hodgkin's lymphomas. <i>American Journal of Hematology</i> , <b>2001</b> , 67, 84-92	7.1	38
3	Apoptotic cells in a peripheral blood smear in the context of EBV infection. <i>American Journal of Hematology</i> , <b>2001</b> , 67, 148-9	7.1	2
2	Conventional chemotherapy for acute myeloid leukemia: a Brazilian experience. <i>Sao Paulo Medical Journal</i> , <b>2000</b> , 118, 173-8	1.6	11
1	Múltiplas infecções oportunistas em um paciente com leucemia linfocítica crônica tratado com cladribina. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , <b>2000</b> , 22, 420		